Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
 free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 free
 free
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
Treatment options for sexual dysfunction in patients with chronic kidney disease: a systematic review of randomized controlled trials Vecchio M; Navaneethan SD; Johnson DW; Lucisano G; Graziano G; Querques M; Saglimbene V; Ruospo M; Bonifati C; Jannini EA; Strippoli GFClin J Am Soc Nephrol 2010[Jun]; 5 (6): 985-95BACKGROUND AND OBJECTIVES: Sexual dysfunction is very common in patients with chronic kidney disease (CKD), but treatment options are limited. The benefits and harms of existing interventions for treatment of sexual dysfunction were assessed in patients with CKD. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: MEDLINE (1966 to December 2008), EMBASE (1980 to December 2008), and the Cochrane Trial Registry (Issue 4 2008) were searched for parallel and crossover randomized and quasi-randomized trials. Treatment effects were summarized as mean differences (MD) or standardized mean difference (SMD) with 95% confidence intervals (CI) using a random effects model. RESULTS: Fourteen trials (328 patients) were included. Phosphodiesterase-5 inhibitors (PDE5i) compared with placebo significantly increased the overall International Index of Erectile Function-5 (IIEF-5) score (three trials, 101 patients, MD 1.81, 95% CI 1.51 to 2.10), all of its individual domains, and the complete 15-item IIEF-5 (two trials, 80 patients, MD 10.64, 95% CI 5.32 to 15.96). End-of-treatment testosterone levels were not significantly increased by addition of zinc to dialysate (two trials, 22 patients, SMD 0.19 ng/dl, 95% CI -2.12 to 2.50), but oral zinc improved end-of-treatment testosterone levels. There was no difference in plasma luteinizing and follicle-stimulating hormone level at the end of the study period with zinc therapy. CONCLUSIONS: PDE5i and zinc are promising interventions for treating sexual dysfunction in CKD. Evidence supporting their routine use in CKD patients is limited. There is an unmet need for studying interventions for male and female sexual dysfunction in CKD considering the significant disease burden.|*Dietary Supplements/adverse effects[MESH]|*Phosphodiesterase 5 Inhibitors[MESH]|Administration, Oral[MESH]|Adult[MESH]|Biomarkers/blood[MESH]|Chronic Disease[MESH]|Cyclic Nucleotide Phosphodiesterases, Type 5/metabolism[MESH]|Erectile Dysfunction/drug therapy/etiology[MESH]|Evidence-Based Medicine[MESH]|Female[MESH]|Follicle Stimulating Hormone, Human/blood[MESH]|Humans[MESH]|Kidney Diseases/*complications[MESH]|Luteinizing Hormone/blood[MESH]|Male[MESH]|Middle Aged[MESH]|Phosphodiesterase Inhibitors/adverse effects/*therapeutic use[MESH]|Randomized Controlled Trials as Topic[MESH]|Sexual Dysfunction, Physiological/*drug therapy/enzymology/etiology[MESH]|Testosterone/blood[MESH]|Treatment Outcome[MESH]|Zinc/*administration & dosage/adverse effects/blood[MESH] |
